<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140004050A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140004050</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13932085</doc-number><date>20130701</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>49</main-group><subgroup>00</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>G</section><class>01</class><subclass>N</subclass><main-group>21</main-group><subgroup>64</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>49</main-group><subgroup>006</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>G</section><class>01</class><subclass>N</subclass><main-group>21</main-group><subgroup>6486</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><classification-national><country>US</country><main-classification>424  96</main-classification><further-classification>435 25</further-classification></classification-national><invention-title id="d0e43">SELF-QUENCHING ACTIVATABLE COX-2-SPECIFIC MULTI-MODAL MOLECULAR PROBES FOR DIAGNOSIS OF CANCERS, INFLAMMATION, AND IMMUNE SYSTEM DISORDERS</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>61667076</doc-number><date>20120702</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>The Board of Trustees of the Leland Stanford Junior University</orgname><address><city>Palo Alto</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Rajadas</last-name><first-name>Jayakumar</first-name><address><city>Cupertino</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Gonzalez</last-name><first-name>Emilio</first-name><address><city>Madrid</city><country>ES</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Ra</last-name><first-name>Hyejun</first-name><address><city>Sunnyvale</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Ali-Khan</last-name><first-name>Irfan</first-name><address><city>Saratoga</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>Contag</last-name><first-name>Christopher</first-name><address><city>San Jose</city><state>CA</state><country>US</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Encompassed are pharmaceutically acceptable compositions formulated for the topical or transdermal delivery of probes specific for cyclooxygenase-2 (COX-2) of human and non-human subjects. In particular, an activatable probe comprises a fluorescent moiety comprising a fluorophore attached to a compound having selective affinity for COX-2, and a removable fluorescence quencher linked to the fluorescent moiety by a cleavable linker. Upon delivery to a recipient subject, the activatable probe is localized and concentrated in tissues and cells with elevated levels of COX-2. The linker is cleaved to release the fluorescence quencher. Irradiation by an activating incident illumination results in a detectable fluorescent emission signal</p></abstract></us-patent-application>